Premium
P4‐279: IDENTIFICATION OF A SIMPLE AND NOVEL DIAGNOSTIC FOR PREDICTING ALZHEIMER'S DISEASE PROGRESSION REINFORCES THE 2018 NIA‐AA RESEARCH FRAMEWORK
Author(s) -
Devanarayan Priya,
Devanarayan Viswanath,
Llano Daniel A.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.07.101
Subject(s) - alzheimer's disease neuroimaging initiative , neuroimaging , magnetic resonance imaging , neurodegeneration , cognitive impairment , medicine , oncology , pathology , disease , psychology , neuroscience , radiology
associative trend with improvements in NPI-A/A with nabilone compared to placebo (b1⁄4-5.3, 95% -11.02 to 0.35, p1⁄40.065). Increases in Cchol levels from BL had an associative trend with a reduction in NPI-A/A with nabilone compared to placebo (b1⁄44.0, 95% -8.24 to 0.27, p1⁄40.067). In thosewith minimal to marked improvement on the CGIC during nabilone (N1⁄417), increases in Cchol levels from BL were significantly associated with a reduction in NPI-A/A in nabilone compared to placebo (b1⁄4-8.1, 95% CI -12.7 to -3.5, p1⁄40.001). Conclusions: These findings suggest that serum Cchol may be a marker of agitation severity in AD, and a marker of treatment response to nabilone.